Meet Thoracic Surgeon David Jones
David Jones is a surgeon who cares for patients with cancers of the chest, including lung and esophageal cancers. As Chief of the Thoracic Surgery Service, he shares his thoughts on the future of treatment for these diseases and offers insight into the strengths of the Memorial Sloan Kettering surgical team. In addition to seeing patients in Manhattan, Dr. Jones will soon be practicing at MSK's new ambulatory cancer care facility opening in West Harrison, NY in October 2014.
On Cancer - July 14, 2014Meet Medical Oncologist William Tap
William Tap is Chief of Memorial Sloan Kettering’s Sarcoma Medical Oncology Service. Learn more about how he chose a career in providing cutting-edge treatment to people with different types of soft tissue sarcoma and why patients benefit from coming to Memorial Sloan Kettering for treatment.Read more
On Cancer - July 17, 2014Hsp90: A Very Promising Target for Cancer Therapy
Drug discovery is “a long, complex effort,” says chemical biologist Gabriela Chiosis, a member of the Sloan Kettering Institute’s Molecular Pharmacology and Chemistry Program. She should know. The journey to the discovery in her laboratory of how a small molecule can be used to block the activity of a cancer-promoting protein began more than a decade ago.Read more
Pancreatic Cancer Research Center Takes Transformative Approach
Pancreatic cancer is an especially arduous disease, rarely detected early and very challenging to treat. While great progress has been made with many other malignancies, pancreatic cancer has yielded little in the way of clinical advances, and most patients still die from the affliction.Read full article in Center News
Aggressive Ovarian Cancer May Be Caused by a Single Gene Mutation
Memorial Sloan Kettering researchers have identified a genetic mutation that appears to cause a rare but very aggressive type of ovarian cancer in young women. The discovery could be an important step toward developing the first effective treatments for the disease, called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Funded initially by a charitable organization, the research is also an example of the powerful effect philanthropy can have on rare diseases.